Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination

Vaccine

Volumn 26, Issue 9, 2008, Pages 1173-1184

  Martins, Marina Ângela ^a,b   Silva, Maria Luiza ^a,b   Elói Santos, Silvana Maria ^a,b   Ribeiro, José Geraldo Leite ^c   Peruhype Magalhães, Vanessa ^a   Marciano, Ana Paula Vieira ^a   Homma, Akira ^a   Kroon, Erna Geessien ^b   Teixeira Carvalho, Andréa ^a   Martins Filho, Olindo Assis ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Ministério da Saúde Núcleo Estadual de Minas Gerais   (Brazil)

Author keywords

17DD vaccine; Innate immunity; Yellow fever

Indexed keywords

CD23 ANTIGEN; CD28 ANTIGEN; CHEMOKINE RECEPTOR; FC RECEPTOR; HLA DR ANTIGEN; INTERLEUKIN 10 RECEPTOR; LIVE VACCINE; YELLOW FEVER VACCINE;

ADULT; ARTICLE; CELL ACTIVATION; FEMALE; GRANULOCYTE; HUMAN; HUMAN EXPERIMENT; INNATE IMMUNITY; MALE; MONOCYTE; NATURAL KILLER CELL; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; UPREGULATION; VACCINATION; VIRUS STRAIN; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

ADULT; FEMALE; GRANULOCYTES; HUMANS; IMMUNITY, NATURAL; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, IGG; RECEPTORS, INTERLEUKIN-10; UP-REGULATION; VACCINATION; VACCINES, ATTENUATED; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 39149107106     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.035     Document Type: Article

References (56)

1. Robertson S., Hull B.P., Tomori O., Bele O., LeDuc J.W., and Esteves K. Yellow fever: a decade of reemergence. J Am Med Assoc 276 (1996) 1157-1162
2. Vasconcelos P.F. Yellow fever: reflections on the disease, prospects for the century and risk of re-urbanization. Braz J Epidemiol 5 (2002) 244-258
3. Freestone D.S. Yellow fever vaccine. In: Plotkin S.A., and Mortimer E.A. (Eds). Vaccines. 2nd ed. (1994), W.B. Saunders, Philadelphia 741-779
4. Monath T.P. Yellow fever. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), W.B. Saunders Company, Philadelphia 815-879
5. Poland J.D., Calisher C.H., Monath T.P., Downs W.G., and Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Org 59 (1981) 895-900
6. World Health Organization. Global programme for vaccines and immunization/Division of emerging and other communicable diseases surveillance and control. Yellow fever-technical consensus meeting. Geneva; 1998. [Document WHO/EPI/GEN/98.08].
7. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., and Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358 (2001) 121-122
8. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358 (2001) 98-104
9. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17D vaccine in Brazil: a report of two cases. Lancet 358 (2001) 91-97
10. Barba-Spaeth G., Longman R.S., Albert M.L., and Rice C.M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202 (2005) 1179-1184
11. Co M.D., Terajima M., Cruz J., Ennis F.A., and Rothman A.L. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293 (2002) 151-163
12. Martins M.A., Silva M.L., Marciano A.P., Peruhype-Magalhães V., Eloi-Santos S.M., Ribeiro G.L., et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?. Clin Exp Immunol 148 1 (2007) 90-100
13. German R.N. An innately interesting decade of research in immunology. Nat Med 10 (2004) 1307-1320
14. Navarro-Sánchez E., Desprès P., and Cedillo-Barrón L. Innate immune responses to Dengue Virus. Arch Med Res 36 (2005) 425-435
15. Querec T., Bennouna S., Alkan S., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203 (2006) 413-424
16. Querec T.D., and Pulendran B. Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D. Adv Exp Med Biol 590 (2007) 43-53
17. Quaresma J.A.S., Barros V.L.R.S., Pagliari C., et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-β TNF-α and NK cells activity. Virology 345 (2006) 22-30
18. Stefano I., Sato H.K., Pannuti C.S., et al. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 17 (1999) 1042-1046
19. Theofilopoulos A.N., Brandt W.E., Russell P.K., and Dixon F.T. Replication of dengue-2 virus in cultured human lymphoblastoid cells and subpopulations of human peripheral leukocytes. J Immunol 117 (1976) 953-961
20. Juffrie M., Van Der Meer G.M., Hack C.E., Haasnoot K., Sutaryo, Veerman A.J., et al. Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect Immun 68 (2000) 702-707
21. Lecoanet-Henchoz S.J.P., Gauchat J.P., Aubry P., Graber P., Life B., Ferrua A.L., et al. CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b and CD 18 and CD11c-CD18. Immunity 3 (1995) 119-125
22. Venuprasad K., Chattopadhyay S., and Saha B. CD28 signaling in neutrophil induces T-cell chemotactic factor(s) modulating T-cell response. Hum Immunol 64 (2003) 38-43
23. Venuprasad K., Parab P.B., Prasad D.V.R., Sharma S., Banerjee P.P., Deshpande M., et al. CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression. Eur J Immunol 31 5 (2001) 1536-1543
24. Woerly G., Roger N., Loiseau S., Dombrowicz D., Capron A., and Capron M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon-γ): inhibition by immunoglobulin A complexes. J Exp Med 190 (1999) 487-495
25. Elbim C., Reglier H., Fay M., Delarche C., Andrieu V., El Benna J., et al. Intracellular pool of IL-10 receptors in specific granules of human neutrophils: differential mobilization by proinflammatory mediators. J Immunol 166 8 (2001) 5201-5207
26. Bussolati B., Mariano F., Montrucchio G., Piccoli G., and Camussi G. Modulatory effect of interleukin-10 on the production of platelet-activating factor and superoxide anions by human leukocytes. Immunology 90 (1997) 440-447
27. Capsoni F., Minonzio F., Ongari A.M., Carbonelli V., Galli A., and Zanussi C. Interleukin-10 down-regulates oxidative metabolism and antibody-dependent cellular cytotoxicity of human neutrophils. Scand J Immunol 45 (1997) 269-275
28. Chaves M.M., Silvestrini A.A., Silva-Teixeira D.N., and Nogueira-Machado J.A. Effect in vitro of interferon-γ and interleukin-10 on generation of oxidizing species by human granulocytes. Inflamm Res 45 (1996) 313-315
29. Laichalk L., Danforth J.M., and Standiford T.J. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol 15 (1996) 181-187
30. Liprandi F., and Walder R. Replication of virulent and attenuated strains of yellow fever virus in human monocytes and macrophages-like cells (U937). Arch Virol 76 (1983) 51-61
31. Halstead S.B., and O'Rourke E.J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146 (1977) 201-217
32. Thieblemont N., Weiss L., Sadeghi H.M., Estcourt C., and Haeffner-Cavaillon N. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol 23 (1995) 3418-3424
33. ++ monocytes are a major source of TNF. J Immunol 168 7 (2002) 3536-3542
34. Randolph G.J., Sanchez-Schmitz G., Liebman R.M., and Schakel K. The CD16+(FcγRIII+) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 196 (2002) 517-527
35. Hacker U.T., Jelinek T., Erhardt S., Eigler A., Hartmann G., Nothdurft H.D., et al. In vivo synthesis of tumor necrosis factor-a in healthy humans after live yellow fever vaccination. J Infect Dis 177 (1998) 774-778
36. Van de Winkel J.G. Biology of human immunoglobulin G Fc receptors. J Leukoc Biol 49 (1991) 511-524
37. Gerber J.S., and Mosser D.M. Stimulatory and inhibitory signals originating from the macrophage Fc gamma receptors. Microbes Infect 3 2 (2001) 131-139
38. de Waal Malefyt R., Abrams J., Bennett B., Figdor C., and de Vries J. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174 (1991) 1209-1220
39. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M.H., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 147 (1991) 3815-3822
40. de Waal Malefyt R., Figdor C.G., Huijbens R., Mohan P.S., Bennett B., Culpepper J., et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes, comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 151 (1993) 6370-6381
41. Gruber M.F., Williams C.C., and Gerrard T.L. Macrophage-colony-stimulating factor expression by anti-CD45 stimulated human monocytes is transcriptionally up-regulated by IL-1 beta and inhibited by IL-4 and IL-10. J Immunol 152 (1994) 1354-1361
42. Berkman N., John M., Roesems G., Jose P.J., Barnes P.J., and Chung K.F. Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. J Immunol 155 (1995) 4412-4418
43. Rossi D.L., Vicari A.P., Franz-Bacon K., McClanahan T.K., and Zlotnik A. Identification through bioinformatics of two new macrophage proinflammatory human chemokines MIP 3-α and MIP 3-β. J Immunol 158 (1997) 1033-1036
44. Kopydlowski K.M., Salkowski C.A., Cody M.J., van Rooijen N., Major J., Hamilton T.A., et al. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 163 (1999) 1537-1544
45. Niiro H., Otsuka T., Kuga S., Nemoto Y., Abe M., Hara N., et al. IL-10 inhibits prostaglandin E2 production by lipopolysaccharide stimulated monocytes. Int Immunol 6 (1994) 661-664
46. Mertz P.M., DeWitt D.L., Stetler-Stevenson W.G., and Wahl L.M. Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem 269 (1994) 21322-21329
47. Muzio M., Bosisio D., Polentarutti N., D'Amico G., Stoppacciaro A., Mancinelli R., et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164 (2000) 5998-6004
48. Buechler C., Ritter M., Orso E., Langmann T., Klucken J., and Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol 67 (2000) 97-103
49. Moore K.W., De Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
50. - cells with low activity are possible precursors of mature natural killer cells. Cell Immunol 180 (1997) 132-142
51. Carson W.E., Lindemann M.J., Baiocchi R., Linett M., Tan J.C., Chou C.C., et al. The functional characterization of interleukin-l0 receptor expression on human natural killer cells. Blood 85 (1995) 3577-3585
52. Glass W.G., Lim J.K., Cholera R., Pletnev A.G., Gao J.L., and Murphy P.M. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 202 (2005) 1087-1098
53. Shirato K., Kimura T., Mizutani T., Kariwa H., and Takashima I. Different chemokine expression in lethal and non-lethal murine West Nile virus infection. J Med Virol 74 (2004) 507-1313
54. Glass W.G., McDermott D.H., Lim J.K., Lekhong S., Yu F., Frank W.A., et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203 1 (2006) 35-40
55. Svetlana F.K., Albert A.R., Michael R.H., and Stephen St. Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology 342 (2005) 167-176
56. ter Meulen J., Sakho M., Koulemou K., Magassouba N., Bah A., Preiser W., et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis 190 (2004) 1821-1827